Hepan

Hepan is a prescription medication that combines heparin sodium and dexpanthenol. It is supplied as a sterile solution intended for subcutaneous injection. The formulation provides anticoagulant activity from heparin and supports tissue repair through the provitamin B5 derivative dexpanthenol. Hepan is marketed in the European Union and requires a physician’s order.

Hepan is used in clinical practice to manage and prevent thrombotic conditions while also supporting local tissue healing at the injection site.

- Anticoagulation for prevention of venous thromboembolism in at‑risk patients - Treatment of acute deep‑vein thrombosis and pulmonary embolism - Prophylaxis of clot formation after surgical procedures - Adjunct therapy to maintain catheter patency - Support of wound‑healing processes due to dexpanthenol content

Side effects associated with Hepan can vary in frequency and severity. Patients should be informed about both common and serious reactions.

Common: - Mild pain, redness, or bruising at the injection site - Minor bleeding or hematoma formation - Transient itching or rash near the administration area - Slight increase in bleeding time during routine procedures

Serious: - Heparin‑induced thrombocytopenia (HIT) with potential for new clots - Major or uncontrolled bleeding events - Severe allergic reactions such as anaphylaxis - Skin necrosis or ulceration at injection sites - Paradoxical thrombosis despite anticoagulation

When prescribing or administering Hepan, healthcare professionals should consider several safety measures to minimize risk.

- Assess patient’s bleeding risk and review recent surgeries or trauma - Monitor platelet counts regularly to detect possible HIT - Avoid use in patients with active uncontrolled bleeding - Use caution in renal or hepatic impairment, adjusting therapy as needed - Consider age‑related dosing adjustments for elderly patients - Review concomitant use of other anticoagulants or antiplatelet agents - Pregnancy status is not well defined; evaluate benefits versus risks

Hepan may interact with other medications that affect hemostasis or platelet function. Awareness of these interactions helps prevent adverse events.

Avoid: - Other anticoagulants (e.g., warfarin, direct oral anticoagulants) - Antiplatelet drugs such as aspirin, clopidogrel, or ticagrelor - Thrombolytic agents and fibrinolytics - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase bleeding risk

Use with caution: - Hormonal contraceptives or estrogen therapy - Certain antibiotics (e.g., vancomycin) that may potentiate thrombocytopenia - Chemotherapy agents that affect platelet production - Corticosteroids that can alter coagulation parameters - Vitamin K antagonists requiring close INR monitoring